In summary, this study evaluated EGFR and KRAS mutations in matched tissue and preoperative plasma samples from surgically resected NSCLC and assessed the clinicopathological predictors for ctDNA release in plasma. Here, KRAS is linked to non-small cell lung carcinoma.